Natural Killer Cell Reduction and Uteroplacental Vasculopathy

Michaela Golic1, Nadine Haase1, Florian Herse1

  • 1From the Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité - Universitätsmedizin Berlin, Germany (M.G., N.H., F.H., A.W., A.B., F.C.L., L.P., D.N.M., R.D.); Department of Obstetrics (M.G., S.V., W.H.) and Department of Gynecology (M.G.), Charité - Universitätsmedizin Berlin, Germany; Berlin Institute of Health (BIH), Germany (M.G., N.H., F.H., A.W., A.B., F.C.L., L.P., S.V., D.N.M., R.D.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., F.H., A.B., D.N.M.); Charité - Universitätsmedizin Berlin, Campus Berlin Buch, Germany (A.W., F.C.L., L.P., R.D.); Department of Development and Regeneration, University Hospital Leuven, Belgium (L.V., R.P.); Department of Medical Biology, János Szentágothai Research Centre Pécs, University of Pécs Medical School, Hungary (A.B.); Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Norway (P.C.S., E.D.); Department of Multi-Disciplinary Laboratory Medicine and Medical Biochemistry, Akershus University Hospital, Lørenskog, Norway (P.C.S.); Clinic for Nephrology and Hypertension, Hannover Medical School, Germany (J.-K.P.); University of Oslo, Norway (P.A.-K., A.C.S.); Department of Obstetrics and Gynecology, Oslo University Hospital, Norway (P.A.-K., A.C.S.); and Department of Cardiology and Nephrology, HELIOS Klinikum Berlin, Germany (R.D.).